ArticleScientific reports2025
Retrospective analysis of clinical and epidemiological characteristics of Chinese cobra bites in a South China emergency department.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In China, it is estimated that over 100,000 snakebite incidents occur each year, significantly endangering human life. This study retrospectively analyzed the treatment data of Chinese cobra bite patients in a Chinese hospital from 2010 to July 2017. It was found that local necrosis typically occurs after a Chinese cobra bite, and effective treatment involves removal of the necrotic tissue and facilitating wound healing with anti-infection measures. The extent of local damage after the bite was correlated with creatine kinase levels. In addition, early administration of Chinese cobra antivenom was beneficial as it alleviated local necrosis and reduced the likelihood of adverse complications. However, under the current treatment protocols, the use or nonuse of Chinese cobra antivenom does not significantly impact survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.